2 August 2022

Dr. Milan Crnogorac joins Swiss Rockets AG as Chief Technology Officer

Swiss Rockets AG completes its leadership team by hiring Dr. Milan Crnogorac as Chief Technology Officer as of 1 August 2022.

Dr. Milan Crnogorac is Chief Technology Officer for all Swiss Rockets Group companies. He is responsible for the strategic, financial, and operational management of technical operations, project management, and capital expenditure.

Dr. Crnogorac has more than 20 years of international experience in the pharmaceutical industry in product and process development, technology transfer, and quality and business development in established and emerging markets – in both start-up and "big pharma" environments. He spent the last 17 years at Genentech and Roche in various management positions. Prior to joining Swiss Rockets AG, he was Global Head of External Quality Validation at Roche in Basel, where he was responsible for successful product launches, technology transfers, and in-licensing activities within Roche's commercial supplier network (CDMO).

Dr. Crnogorac is widely recognized for his ability to balance business and technical needs in the areas of stakeholder management, asset management, negotiations, and value creation. He holds a B.S. in Chemistry from the University of Belgrade and a Ph.D. in Chemistry from the Iowa State University.

About Swiss Rockets AG: 

Founded in 2018, Swiss Rockets AG is implementing a paradigm shift in healthcare. Patients benefit from new therapies developed with innovative and pioneering methods. The Swiss Rockets AG team combines expertise and experience to create innovative medicines focused on cancer and viral diseases.

The founders of Swiss Rockets AG are Dr. Vladimir Cmiljanovic, Dr. Natasa Cmiljanovic, Manuel Ebner, Dr. Thomas Sander and Dr. Thomas Staehelin. Vladimir Cmiljanovic is the CEO, a medicinal chemist, and entrepreneur with more than 15 years of experience in cancer drug development. He is the founder of the Swiss biotech companies PIQUR AG and TargImmune AG. With his sister Dr. Natasa Cmiljanovic, the Chief Scientific Officer of Swiss Rockets AG, he has developed cancer drugs at the University of Basel. He has also founded and managed several biotech companies. Manuel Ebner is a Managing Director at Bank of America Merrill Lynch, Switzerland, and a strategic advisor to Swiss Rockets AG. Dr. Thomas Sander, one of the first employees of Actelion's biotech company, is a scientific advisor to Swiss Rockets AG. Dr. Thomas Staehelin, the co-founder of Swiss Rockets AG, is a member of the Executive Board and Chairman of several shareholder companies and foundations.

Members of the Board of Directors of Swiss Rockets AG are Dr. Vladimir Cmiljanovic (Chairman), Prof. Dr. Michael N. Hall, a renowned researcher and professor at the Center for Molecular Biosciences at the University of Basel, Dr. Natasa Cmiljanovic, a medicinal chemist and clinical scientist with experience in the development of cancer drugs, Dr. Thomas Ladner, a business lawyer, founder and co-founder of several successful start-ups and the World. Minds Foundation, and André Debrunner, a financial expert and fund manager at Northern Trust Switzerland AG.